CARD11 Inhibitors

Chemical inhibitors of CARD11 operate through various mechanisms to modulate the activity of this protein. Lenalidomide acts by promoting the ubiquitination and subsequent degradation of IκB kinase (IKK). The degradation of IKK prevents the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a critical downstream target of CARD11 signaling. Similarly, Bortezomib disrupts the NF-κB pathway by inhibiting the proteasome responsible for degrading IκB, an inhibitor of NF-κB, thus preventing NF-κB activation. Thalidomide also modulates CARD11 activity by preventing IκB degradation, leading to suppression of NF-κB. Ibrutinib, on the other hand, binds irreversibly to Bruton's tyrosine kinase (BTK), an enzyme upstream of CARD11 in the B-cell receptor signaling pathway, resulting in reduced CARD11 signaling.

Other inhibitors target various kinases that interact with CARD11 signaling pathways. Sorafenib inhibits multiple protein kinases, including those in the MAPK pathway, which interacts with CARD11 signaling, thereby reducing CARD11-mediated NF-κB activation. Sunitinib and Dasatinib inhibit tyrosine kinases that are involved in the activation of CARD11, leading to decreased CARD11-mediated signaling. Rapamycin and AZD8055 inhibit mTOR, a pathway connected to CARD11 function, which in turn reduces the activity of CARD11. U0126 interrupts the CARD11 signaling cascade by inhibiting MEK1/2, kinases in the MAPK/ERK pathway. Similarly, SP600125 inhibits JNK, part of stress-activated protein kinase pathways that influence CARD11 activity. Lastly, Ixazomib, like Bortezomib, inhibits the proteasome, leading to an accumulation of IκB and inhibition of the NF-κB pathway, culminating in a reduction of CARD11 dependent processes.